Bupropion-Naltrexone Bests Placebo in Methamphetamine Use Disorder
Response was low but higher with naltrexone-bupropion than placebo during 12-week, two-stage trial
Response was low but higher with naltrexone-bupropion than placebo during 12-week, two-stage trial
The unapproved and misbranded opioids, which include tramadol and oxycodone, are being sold without a prescription.
Percentages much higher for actively prescribing U.S. clinicians with 275 and 100 versus 30 patients
Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it’s shelf life extended. Also, we recap drug pipeline news from the past week.
Abstinence from cannabis increased with cannabidiol 400mg, 800mg doses compared with placebo.
The FDA has announced that it is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder to include new recommendations about naloxone to the prescribing information.
Evidence inadequate to assess benefits and harms of screening for unhealthy drug use in teens.
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
Alkermes has decided to expand the number of retail pharmacies and clinics where patients can receive access to Aristada (aripiprazole lauroxil) and Vivitrol (naltrexone extended-release injectable suspension).
Cases of e-cigarette or vaping product use–associated lung injury (EVALI) appear to have been overlooked in the past.